Search Legislation

The Medicines for Human Use (Clinical Trials) Regulations 2004

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about opening options

Opening OptionsExpand opening options

Changes over time for: Section 35

 Help about opening options

Changes to legislation:

The Medicines for Human Use (Clinical Trials) Regulations 2004, Section 35 is up to date with all changes known to be in force on or before 27 February 2025. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations. Help about Changes to Legislation

Annual list of suspected serious adverse reactions and safety reportU.K.

35.—(1) As soon as practicable after the end of the reporting year, a sponsor shall, in relation to each investigational medicinal product tested in clinical trials in the United Kingdom for which he is the sponsor furnish the licensing authority and the relevant ethics committees with—

(a)a list of all the suspected serious adverse reactions which have occurred during that year in relation to—

(i)those trials, whether at trial sites in the United Kingdom or elsewhere, or

(ii)any other trials relating to that product which are conducted outside the United Kingdom and for which he is the sponsor,

including those reactions relating to any investigational medicinal product used as a placebo or as a reference in those trials; and

(b)a report on the safety of the subjects of those trials.

(2) In paragraph (1), “reporting year”, in relation to an investigational medicinal product, means the year ending on the anniversary of—

(a)in the case of a product which has a marketing authorization, the earliest date on which any such authorization relating to that product was granted or issued; or

(b)in any other case, the earliest date on which any clinical trial—

(i)relating to that product, and

(ii)for which the person responsible for making the report was the sponsor,

was authorised in an [F1any country].

(3) For the purposes of paragraph (2)(b), the date on which a clinical trial was authorised in [F2a country] is—

[F3(a)the date on which the trial was authorised by a regulatory body responsible for authorising clinical trials in that country; or

(b)where the clinical trial was conducted in a country without a formal authorisation process, a date designated by the sponsor that is linked to the commencement of the first clinical trial.]

Back to top

Options/Help